Sepsis Diagnostics in the Era of "Omics" Technologies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10382357" target="_blank" >RIV/00216208:11110/18:10382357 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023884:_____/18:00007485

Výsledek na webu

<a href="https://pmr.lf1.cuni.cz/media/pdf/pmr_2018119010009.pdf" target="_blank" >https://pmr.lf1.cuni.cz/media/pdf/pmr_2018119010009.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14712/23362936.2018.2" target="_blank" >10.14712/23362936.2018.2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sepsis Diagnostics in the Era of "Omics" Technologies

Popis výsledku v původním jazyce

Sepsis is a multifactorial clinical syndrome with an extremely dynamic clinical course and with high diverse clinical phenotype. Early diagnosis is crucial for the final clinical outcome. Previous studies have not identified a biomarker for the diagnosis of sepsis which would have sufficient sensitivity and specificity. Identification of the infectious agents or the use of molecular biology, next gene sequencing, has not brought significant benefit for the patient in terms of early diagnosis. Therefore, we are currently searching for biomarkers, through &quot;omics&quot; technologies with sufficient diagnostic specificity and sensitivity, able to predict the clinical course of the disease and the patient response to therapy. Current progress in the use of systems biology technologies brings us hope that by using big data from clinical trials such biomarkers will be found.

Název v anglickém jazyce

Sepsis Diagnostics in the Era of "Omics" Technologies

Popis výsledku anglicky

Sepsis is a multifactorial clinical syndrome with an extremely dynamic clinical course and with high diverse clinical phenotype. Early diagnosis is crucial for the final clinical outcome. Previous studies have not identified a biomarker for the diagnosis of sepsis which would have sufficient sensitivity and specificity. Identification of the infectious agents or the use of molecular biology, next gene sequencing, has not brought significant benefit for the patient in terms of early diagnosis. Therefore, we are currently searching for biomarkers, through &quot;omics&quot; technologies with sufficient diagnostic specificity and sensitivity, able to predict the clinical course of the disease and the patient response to therapy. Current progress in the use of systems biology technologies brings us hope that by using big data from clinical trials such biomarkers will be found.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30223 - Anaesthesiology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Prague Medical Report

ISSN

1214-6994

e-ISSN

—

Svazek periodika

119

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

21

Strana od-do

9-29

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85049266520